Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke

Inclusion Criteria: * Stroke, with cortical and/or subcortical lesions, of at least 6-months duration at study inclusion * Spasticity in the lower extremity plantarflexors (gastrocnemius, soleus muscles) due to stroke with a baseline score of 1-4 as assessed by the Tardieu scale * Minimum 1-month duration of spasticity as confirmed by medical history * Modified Rankin score \< 4 * Cognitive functions sufficient to understand the experiments and follow instructions and ability to provide informed consent in accordance with ICH and GCP * Affiliated with the French social security scheme, universal medical coverages (CMU), or an equivalent scheme. Exclusion Criteria: * Enrollment in another biomedical research study at the time of the MyoRegulator study. * Fixed contractures or profound muscle atrophy in the spastic limb * Ongoing use of digitalis, morphine, intrathecal pump * Plantar orthosis or history of orthopedic surgery that can interfere with gait analysis * Botulinum toxin treatment within 12 weeks of study enrollment * Prior phenol or alcohol injections within 6 months of study enrollment * Change in the antispastic treatment (baclofen, clonidine, benzodiazepine, dantrolene, gabapentine, tizanidin) in the 2 months prior to visit 1. * Allergy to latex * Presence of potential tsDCS risk factors: * Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, cancerous lesions, e…